BioMarker Strategies Awarded $1.5 Million National Cancer Institute Contract to Develop Companion Diagnostic Test to Select Optimal Therapy for Melanoma Patients
Published: Sep 25, 2013
BALTIMORE--(BUSINESS WIRE)--BioMarker Strategies today announced that the National Cancer Institute (NCI) has awarded the company a $1.5 million Small Business Innovative Research (SBIR) Phase II contract to develop PathMAP™, a pathway-based companion diagnostic test to facilitate the selection of optimal therapy for individual patients with melanoma.
Help employers find you! Check out all the jobs and post your resume.